EpiCast Report: Uveitis - Epidemiology Forecast to 2026
Uveitis is the inflammation of the uveal tract (iris, ciliary body, and choroid), but can also cause the inflammation of nearby tissues, such as the retina, the optic nerve, and the vitreous humor. Uveitis can affect one or both eyes. It primarily affects people ages 20-50 years, but can present at any age (Mayo Clinic, 2015). Uveitis is an important cause of blindness and visual loss in many communities (Wakefield and Chang, 2005). The most widely used classification criteria of uveitis is that one outlined by the International Uveitis Study Group (IUSG) (Medscape, 2016).
In the 7MM, the diagnosed incident cases of uveitis will increase from about 0.4million cases in 2016 to around 420,000 cases in 2026, at an Annual Growth Rate (AGR) of over 0.4% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and UK), the diagnosed incident cases of uveitis will increase from over 90,000 cases in 2016 to about 92,000 cases in 2026, at an AGR of around 0.2%.
It is expected that all markets except Germany and Japan will see an increase in the diagnosed incident cases of uveitis during the forecast period. In 2016, there were nearly 1 million diagnosed prevalent cases of uveitis in the 7MM, which are expected to increase to nearly 1.1 million cases by 2026, at an AGR of about 1.2%. Among the 7MM, the US had the highest number of diagnosed prevalent cases of uveitis in 2016 and 2026, at about 360,000 cases and 400,000 cases, respectively.
The report EpiCast Report: Uveitis - Epidemiology Forecast to 2026, provides an overview of the risk factors and the global and historical trends for uveitis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiology forecast of the diagnosed incident and diagnosed prevalent cases of uveitis in these markets from 2016-2026.
The Uveitis EpiCast Report provides an overview of the risk factors and global trends of uveitis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
It also includes a 10-year epidemiology forecast of the diagnosed incident and diagnosed prevalent cases of uveitis in these markets from 2016-2026. The diagnosed incident and prevalent cases are further segmented by sex and age (starting at age 0 years up to ages 80 years and older) and by anatomical site of inflammation (anterior, intermediate, posterior, and panuveitis). The diagnosed incident cases are also segmented by course of disease (acute, chronic, and recurrent).
The uveitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The Uveitis EpiCast report will allow you to -
Develop business strategies by understanding the trends shaping and driving the global uveitis market.
Quantify patient populations in the global uveitis market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for uveitis therapeutics in each of the markets covered.
Understand magnitude of uveitis population by course of disease and anatomical site of inflammation.